Depression of the cellular immune responses in mice with disseminated histoplasmosis is associated with deficient production of interleukin-2 (IL-2) by splenocytes. Therefore, we examined whether a highly purified preparation of IL-2, recombinant human IL-2 (rIL-2), could modify the cellular immune responses in infected mice and whether this lymphokine could alter the severity of histoplasmosis in animals. Exogenous rIL-2, at concentrations of up to 1,000 U/ml, failed to augment the proliferative responses to concanavalin A by unfractionated splenocytes or splenic T cells from mice infected for 1 week. In addition, rIL-2 did not modulate the plaque-forming cell response to sheep erythrocytes by splenocytes from these same mice. However, at week 3, rIL-2 in concentrations ranging from 10 to 1,000 U/ml considerably augmented the proliferative response to concanavalin A and plaque-forming cell response to sheep erythrocytes by splenocytes from infected mice. Kinetics studies demonstrated that rIL-2 exerted maximal immunoregulatory activity when added on day 0 or 1 to cultures of splenocytes. In vivo administration of rIL-2, 200 to 20,000 U/day, for 10 days to normal and 3-week-infected mice did not alter the proliferative activity of splenocytes to concanavalin A; 200,000 U of rIL-2 per day actually depressed the proliferative responses of splenocytes from normal and infected mice. In vivo, rIL-2 did not modify delayed-type hypersensitivity responses to sheep erythrocytes or to histoplasmin by normal and infected mice. Moreover, treatment with rIL-2 in vivo did not reduce the number of Histoplasma CFU in spleens of mice. Thus, despite the immunoenhancing effect of rIL-2 in vitro, this lymphokine failed to exert similar effects in vivo.
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Studies on experimental animals and humans have demonstrated that disseminated infection with Histoplasma capsulatum is associated with disturbances of cell-mediated immunity (3) . However, the mechanisms responsible for these alterations have not been elucidated completely. In mice with disseminated histoplasmosis, there is a severe depression of the in vitro and in vivo cellular immune response (CMI) during the first 4 weeks of infection; concomitantly, two populations of suppressor cells are generated in the spleens of these mice (20) . One population is an Lyt-2+, I-J+ T cell, and the other is a macrophagelike cell that adheres poorly to plastic but well to nylon wool (7, 20) . Thus, suppressor cell activity may partly explain the immunoregulatory perturbations in Histoplasma-infected mice.
Interleukin-2 (IL-2) is a glycoprotein produced by T lymphocytes after stimulation with mitogen or antigen. This lymphokine is essential for the clonal expansion of lymphocytes and can amplify the activity of several populations of effector cells (25) . Recently, Watson et al. (26) reported impaired IL-2 generation by splenocytes from mice at weeks 1 and 3 of H. capsulatum infection. Addition of IL-2-containing supernatants to cultures of splenoctyes from infected mice partially reversed the depressed responses to concanavalin A (Con A) by these cells (26) .
In this study, we examined whether recombinant human IL-2 (rIL-2), a preparation devoid of other immunoregulatory cytokines, can augment the CMI of mice infected with H. capsulatum and whether rIL-2 can modify the severity of infection. The results demonstrate that exogenous rIL-2 greatly augmented the in vitro CMI by splenocytes from MATERIALS AND METHODS Animals. Male C57BL/6 mice were purchased from Jackson Laboratories, Bar Harbor, Maine.
Infection with H. capsulatum. Preparation of yeast cells of H. capsulatum G217-B has been described previously (2). Mice Induction and measurement of DTH. To measure the delayed-type hypersensitivity (DTH) response to SRBC, groups of six mice were sensitized by intravenous injection with 0.2 ml of a 0.01% SRBC suspension. After 5 days, mice were challenged intradermally with 0.05 ml of a 20% SRBC suspension into a hind footpad. Footpad swelling was measured 24 h later with a digital micrometer (Brown and Sharpe Co., North Kingston, R.I.). The DTH response was expressed as the percent increase in footpad size over that measured immediately before SRBC challenge. Additionally, the degree of basal inflammatory response to the injection of the SRBC challenge dose only was measured in footpads of nonimmunized control mice from both the normal and infected groups. The DTH response to histoplasmin in paired control and infected mice was also measured as the percent increase in the footpad swelling 24 h after intradermal challenge with 0.05 ml of histoplasmin at an optimal dilution of 1:25.
Organ culture for H. capsulatum. Spleens from groups of six to eight mice were removed aseptically and homogenized in a Teflon tissue grinder in 10 ml of sterile HBSS. Homogenates were diluted serially, and 0.1 ml of each dilution was plated in triplicate onto brain-heart infusion agar (2% agar [wt/vol]) containing 5% defibrinated SRBC, 0.01% (wt/vol) cysteine hydrochloride, 10 pug of gentamicin per ml, and 1% dextrose. Cultures were incubated at 30°C for 7 to 10 days, and the mycelial colonies were enumerated on a colony counter.
Cell preparation. Pools of at least two spleens were gently teased between two ground-glass slides in HBSS to obtain cell suspensions. The cells were allowed to settle for 5 min to remove tissue debris. For the lymphocyte proliferation assay, splenocytes were suspended in RPMI 1640 medium containing 5% FBS, gentamicin (10 ,ug/ml), and 100 U of nystatin per ml to inhibit growth of H. capsulatum. For the plaque-forming cell (PFC) assay, splenocytes were suspended in RPMI 1640 medium containing 10% FBS, 1% nonessential amino acids, 1% sodium pyruvate, 1% Lglutamine, gentamicin (10,ug/ml) 5 x 10-5 M 2-mercaptoethanol, and 100 U of nystatin per ml.
In some experiments, splenocytes enriched for T lymphocytes were prepared by the nylon wool column method of Julius et al. (13 
RESULTS
Splenocytes from mice infected for 1 week do not respond to rIL-2. During the first 3 weeks of disseminated histoplasmosis in C57BL/6 mice, deficient IL-2 production by splenocytes is coincident with depressed CMI in vitro (26) . Therefore, we explored the possibility that impaired responses by splenocytes from mice at 1 and 3 weeks of infection could be augmented by exogenous IL-2.
As previously demonstrated (3), the proliferative response to Con A by splenocytes from mice infected for 1 week was markedly less than that of splenocytes from age-matched controls (Table 1) . Addition of rIL-2, 100 and 1,000 U/ml, to cultures of normal splenocytes enhanced the response to Con A (P < 0.05). On the other hand, concentrations ranging from 10 to 1,000 U of rIL-2 per ml failed to modify the response to Con A by splenocytes from infected mice, although rIL-2 did increase [3H]thymidine incorporation by cells cultured in medium alone. This nonspecific stimulatory effect occurred in 16 of 20 experiments and has been observed by others (19) . In similar fashion, rIL-2 significantly enhanced (P < 0.01) PFC responses to the heterologous antigen, SRBC, by splenocytes from normal mice. Conversely, it did not augment the response of splenocytes from infected mice ( Table 2) .
Additional experiments were performed to determine whether the impaired response to rIL-2 by spleen cells from infected mice was a consequence of suppressor macrophagelike cells that are nylon wool-adherent. Cells from mice infected for 1 week or from normal controls were passed through nylon wool, and the nonadherent cells (enriched for T cells) were incubated with Con A in the presence or absence of rIL-2. Splenic T cells from normal mice responded poorly to Con A because of the accessory cell depletion, and rIL-2 (1,000 U/ml) increased the response to Con A only 3.5-fold (Table 1) . However, addition of 5% accessory cells (plastic-adherent splenocytes) from either normal or infected mice to normal T cells considerably augmented the response to Con A, and in the presence of rIL-2, the proliferative response of the latter cells was equal to that of unfractionated normal cells (Table 1) .
Depletion of nylon wool-adherent cells from the splenocytes of infected mice resulted in only a slight improvement of the response to Con A by the T-cell-enriched fraction, and rIL-2 increased the response by these cells only twofold. Furthermore rIL-2 enhances responses by splenocytes from mice at week 3 of infection. At week 3, the response to Con A and the PFC response to SRBC by splenocytes from infected mice continued to be diminished (P < 0.01) compared with those of normal splenocytes (Fig. 1) . However, in contrast to the results at week 1, addition of rIL-2 to cultures of splenocytes from infected mice clearly augmented CMI in vitro. rIL-2 (10 U/ml) increased Con A and PFC responses by 29 and 325%, respectively; 100 and 1,000 U/ml caused even greater enhancement of these responses.
To control for the possibility that rIL-2 increased PFC responses to SRBC by polyclonal stimulation of B lymphocytes, spleen cells from normal and infected mice were cultured without SRBC in the presence or absence of rIL-2 (100 U/ml), and the PFC response to SRBC was measured 4 days later. The PFC response by unimmunized splenocytes from normal mice (347 ± 27 PFC/106 cells recovered) was not significantly greater (P > 0.05) than that of unimmunized splenocytes exposed to rIL-2 (247 ± 31 PFC/106 cells recovered); the response of unimmunized splenocytes from infected mice exposed to rIL-2 was <80 PFC/106 cells recovered. Thus, the enhancing effect of rIL-2 in the PFC assay required the presence of antigen.
Splenocytes from mice at weeks 1 and 3 of infection do not mount a proliferative response to specific Histoplasma antigens (3). To determine whether rIL-2 could boost antigenspecific responses, splenocytes from infected mice were stimulated with histoplasmin in the presence or absence of rIL-2. In a typical experiment (of four performed), the response to histoplasmin by splenocytes from mice at week 3 (132 ± 19 cpm) did not differ from that of control splenocytes (180 + 20 cpm). Addition of up to 1,000 U of rIL-2 per ml nonspecifically increased the response to histoplasmin by splenocytes from both infected mice (895 ± 85 cpm) and normal mice (885 + 94 cpm). Kinetics of immunoregulatory activity by rIL-2. rIL-2 (100 U/ml) was added to normal splenocytes and splenocytes from 3-week-infected mice at day 0 of culture and to separate sets of cultures at 1, 2, and 3 days after culture initiation. rIL-2 increased response to Con A (P < 0.05) when added on day 0, 1, or 2 and augmented PFC response (P < 0.01) when added on day 0 or 1 (Fig. 2) . Enhancement was maximal when rIL-2 was added on day 0 or 1. These results strongly suggest that rIL-2 exerts its regulatory activity during the inductive phase of the immune response.
Treatment with rIL-2 in vivo alters in vitro proliferative responses to Con A. The possibility was explored that in vivo administration of rIL-2 could augment the diminished response to Con A by splenocytes from mice at week 3 of infection. Beginning on day 11 after inoculation of H. capsulatum yeast cells, groups of normal and infected mice were injected i.p. with doses of rIL-2 ranging from 200 to 200,000 U/day for 10 days (Table 3) . Animals were then sacrificed, and the ability of splenocytes from normal and infected mice to respond to Con A in vitro was tested in the presence and absence of exogenous rIL-2 (100 U/ml). Treatment with 200 to 20,000 U/day failed to increase the proliferative response to Con A by splenocytes from normal or infected mice in the absence of exogenous rIL-2. Furthermore, the responses of these cells were decreased in both groups given 200,000 U/day. However, addition of rIL-2 (100 U/ml) to cultures of splenocytes from infected mice treated with either 200 or 2,000 U of rIL-2 per day significantly enhanced Con A-induced blastogenesis (P < 0.01). On the other hand, exogenous rIL-2 failed to increase the proliferative response by splenocytes from infected mice treated with 20,000 or 200,000 U of rIL-2 per day (Table 3) .
In vivo rIL-2 and DTH responses. To determine whether rIL-2 treatment altered DTH responses to a nonspecific antigen (SRBC) or to specific antigen (histoplasmin), mice were given 20,000 U of rIL-2 or medium per day for 10 days beginning on day 11 after inoculation; uninfected control mice were treated identically. Subsequently, the DTH response of these four groups to an intradermal challenge with SRBC was assessed 5 days after immunization with SRBC. The mean increase (± SEM) in footpad thickness of rIL-2-treated normal mice (39 ± 2.0%) was vigorous, although slightly less than that of controls given medium (42 ± 3.3%).
In contrast, the footpad thickness of infected mice that were rIL-2 treated increased by only 24 ± 2.3%. This response did not differ from that of infected animals which had not received rIL-2 (27 + 1.2%). The DTH responses to SRBC in both the latter groups were significantly less (P < 0.05) than those in rIL-2-treated and untreated normal mice. The banal inflammatory responses of all four groups ranged from 7 to 9%. Mice also were tested at week 3 of infection for responsiveness to histoplasmin. The increase in footpad thickness (± SEM) of infected mice given rIL-2 (18 ± 1.3%) was equal to that of untreated infected mice (18 ± 1.6%) . Both values, however, were significantly greater (P < 0.05) than the DTH responses of rIL-2-treated normal mice (6 ± 1.1%) and normal mice given medium (7 ± 1.2%). Thus, rIL-2 treat- ment did not augment DTH responses to nonspecific or specific antigen. In vivo rIL-2 and recovery of H. capsulatum from spleens. Studies were undertaken to determine whether rIL-2 could decrease the number of CFU of H. capsulatum recovered from the spleens of mice at 1 or 3 weeks of infection.
Beginning 4 h after intravenous inoculation of 6 x 105 H. capsulatum yeast cells, mice were injected i.p. with rIL-2 in doses ranging from 200 to 200,000 U/day or with excipient medium; treatment was continued for 1 week. Administration of rIL-2, 200 or 20,000 U/day, to mice for 1 week caused a modest (P > 0.05) reduction in the number of H. capsulatum CFU in spleens (Table 4) . Conversely, rIL-2 at 200,000 U/day was associated with an increase in the number of organisms recovered from spleens (0.05 < P < 0.1).
In other experiments, treatment with increasing doses of rIL-2 or medium was initiated on day 11 of infection and continued for 10 days. Mice were then sacrificed, and the spleens were cultured for H. capsulatum. rIL-2 administered for 10 days failed to alter the severity of infection (Table 4) .
DISCUSSION
Among its many biological properties, IL-2 expands in vitro cytotoxic T lymphocytes (15) , increases gamma interferon production (21), indirectly augments natural killer cell activity (28) , and maintains clonal expansion of T lymphocytes (14) . Because of its protean activity, IL-2 has emerged as an important immunomodulator that is potentially useful therapy for immunodeficiency states, infectious diseases, and malignancies.
It has been reported that impaired production of IL-2 by splenocytes from mice with disseminated histoplasmosis correlates with depression of the in vitro and in vivo CMI (27) . Therefore, in the present study, we attempted to determine whether highly purified rIL-2 could alter the defective CMI in infected mice and whether in vivo administration of rIL-2 could modify the severity of infection. The results indicate that high concentrations of rIL-2 (100 to 1,000 U/ml) did not boost the in vitro response to Con A or the PFC response to SRBC by splenocytes from mice at week 1 of infection; conversely, rIL-2 considerably augmented these responses at week 3. Thus, at week 1, splenocytes from infected mice not only fail to produce IL-2 but also demonstrate impaired responsiveness to rIL-2, whereas at week 3, splenocytes regain the ability to respond to rIL-2.
The finding of deficient IL-2 production by splenocytes from mice infected for 1 week in conjunction with impaired responsiveness to IL-2 by these cells has been described in several disease states, including autoimmune diseases in humans (1) and in mice (29) , murine trypanosomiasis (11) , and murine leishmaniasis (22) . In the murine model of disseminated histoplasmosis, several possibilities must be considered to explain the unresponsiveness to high concentrations of rIL-2 by splenocytes at week 1 of infection. First, T cells from infected mice may express fewer IL-2 receptors, thus reducing the binding of rIL-2 by these cells. This is unlikely since phytohemagglutinin-stimulated lymphoblasts from the spleens of infected mice adsorb the same amount of IL-2 as normal splenic lymphoblasts (27) .
Second, the monokine interleukin-1 (IL-1) is a crucial amplifying factor in the activation of T cells. It is possible, therefore, that the defective responsiveness to rIL-2 may be caused by a lack of this cytokine. In fact, generation of IL-1 by plastic-adherent splenocytes from mice at week 1 of H. capsulatum infection is diminished compared with that by adherent splenocytes from normal mice (27) . Nevertheless, addition of normal adherent splenocytes, as a source of IL-1-secreting cells, to T cells from infected mice did not reverse the poor response to Con A in the presence of rIL-2 (Table 1) . Furthermore, preliminary evidence indicates that addition of IL-1 and rIL-2 to cultures of splenocytes from infected mice does not improve response to Con A (G. S. Deepe, unpublished observations). These findings indicate that lack of IL-1 is not a cause of impaired responsiveness to rIL-2.
A third possibility is that splenocytes from infected mice secrete a factor that inhibits IL-2 activity. Indeed, we have described such a factor that is detectable in culture supernatants of Con A-stimulated splenocytes from mice infected for 1 week (27) . It seems likely, therefore, that the inability of rIL-2 to augment immune responses may be partly attributable to this factor. Although the mode of action of this suppressor factor has not yet been elucidated, data in the current study suggest that it is not simply a competitive inhibitor of IL-2, since increasing concentrations of rIL-2 did not alter the proliferative response to Con A.
Finally, restoration of immune responses may require the interaction of IL-2 with other cytokines, or the interaction between these regulatory factors may be critically dependent on the presence of IL-2. At present, there is little experimental evidence that different lymphokines exert common biological effects. Nevertheless, this hypothesis is supported by the fact that several lymphokines must collaborate for optimal production of antibody responses and for induction of cytotoxic T cells (9) . Clearly, the precise mechanisms for IL-2 unresponsiveness both in this model and in others remain to be determined.
In contrast to the results at week 1, rIL-2 augmented the proliferative activity of splenocytes to Con A and the PFC response to SRBC at week 3 of infection. In vitro kinetic experiments demonstrated that rIL-2 enhanced PFC response maximally when added on day 0 or 1. Recent evidence indicates that activated T and B lymphocytes both express IL-2 receptors (17); moreover, IL-2 can directly induce B cell proliferation and immunoglobulin secretion (8) . Therefore, it is important to determine whether the effect of rIL-2 in the PFC assay is mediated through its action on T cells or B cells or both. The kinetics data strongly suggest that the immunoenhancing effect of rIL-2 was mediated through T cells rather than B cells, since the in vitro regulatory effect of rIL-2 was not active at a time when B cells are activated in a PFC assay (12, 24) .
rIL-2 enhanced the in vitro CMI response of splenocytes from 3-week-infected mice and normal controls; however, administration of rIL-2 in vivo did not improve DTH responses of infected mice to SRBC or histoplasmin. Surprisingly, rIL-2 at 200,000 U/day impaired the proliferative response to Con A by splenocytes from these same animals. This phenomenon has also been observed in humans; intravenous injection of rIL-2 in massive doses depresses the proliferative responses of peripheral blood mononuclear cell to phytohemagglutinin (16) . The reasons for this paradoxical effect of rIL-2 in both species are poorly understood. Since it has been proposed that rIL-2 causes an alteration in lymphocyte recirculation (16) , it is conceivable that there is an emigration of cell populations that are mitogen responsive from the spleen.
The severity of several experimental infections has been modified by treatment with rIL-2 alone. Administration of rIL-2 enhances the survival of mice inoculated with Toxoplasma gondii (25) and protects guinea pigs against challenge with herpes simplex virus (A. Weinberg, L. E.
Rasmussen, and T. C. Merigan, Program Abstr. 25th
Intersci. Conf. Antimicrob. Agents Chemother., abstr. no. 87, 1985) . In addition, rIL-2 reduces the number of circulating Trypanosoma cruzi organisms in the blood of mice and prolongs survival (5) . Notwithstanding the salutary effects of rIL-2 in these infections, the pleiotropic effects of this lymphokine on CMI in experimental histoplasmosis are insufficient to decrease the CFU of H. capsulatum in spleens of mice whether it is administered early or later during the course of infection. Why rIL-2 lacks therapeutic efficacy in this model is not clear. However, it is possible that the activity of rIL-2 in vivo may be compromised by (i) a suppressor factor that is produced by splenocytes from infected mice (26) , (ii) a previously described serum inhibitor of IL-2 activity (10), or (iii) the short half-life of IL-2 in vivo (4).
In conclusion, we have demonstrated that exogenous rIL-2 can augment nonspecific CMI of mice in vitro at week 3 of H. capsulatum infection, but splenocytes from mice infected for 1 week are unresponsive. Moreover, at the doses used in vivo, rIL-2 did not modify the severity of experimental disseminated histoplasmosis. Further studies that examine the efficacy of rIL-2 in conjunction with antimycotic agents or other cytokines or with passive transfer of immune lymphocytes may be of value.
